» Articles » PMID: 17764538

ADAMTS-13, Von Willebrand Factor and Related Parameters in Severe Sepsis and Septic Shock

Overview
Publisher Elsevier
Specialty Hematology
Date 2007 Sep 4
PMID 17764538
Citations 73
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Insufficient control of von Willebrand factor (VWF) multimer size as a result of severely deficient ADAMTS-13 activity results in thrombotic thrombocytopenic purpura associated with microvascluar thrombosis and platelet consumption, features not seldom seen in severe sepsis and septic shock.

Methods: ADAMTS-13 activity and VWF parameters of 40 patients with severe sepsis or septic shock were compared with those of 40 healthy controls of the same age and gender and correlated with clinical findings and sepsis outcome.

Results: ADAMTS-13 activity was significantly lower in patients than in healthy controls [median 60% (range 27-160%) vs. 110% (range 63-200%); P < 0.001]. VWF parameters behaved reciprocally and both VWF ristocetin cofactor activity (RCo) and VWF antigen (VWF:Ag) were significantly (P < 0.001) higher in patients compared with controls. Neither ADAMTS-13 activity nor VWF parameters correlated with disease severity, organ dysfunction or outcome. However, a contribution of acute endothelial dysfunction to renal impairment in sepsis is suggested by the significantly higher VWF propeptide and soluble thrombomodulin levels in patients with increased creatinine values as well as by their strong positive correlations (creatinine and VWF propeptide r(s) = 0.484, P < 0.001; creatinine and soluble thrombomodulin r(s) = 0.596, P < 0.001).

Conclusions: VWF parameters are reciprocally correlated with ADAMTS-13 activity in severe sepsis and septic shock but have no prognostic value regarding outcome.

Citing Articles

Proteomic profiling of plasma extracellular vesicles identifies signatures of innate immunity, coagulation, and endothelial activation in septic patients.

Park C, Ryu T, Mohamed-Hinds R, Kim K, Kim J, Zou L medRxiv. 2025; .

PMID: 40061316 PMC: 11888535. DOI: 10.1101/2025.02.21.25322420.


The Highs and Lows of ADAMTS13 Activity.

Shaw R, Abrams S, Badu S, Toh C, Dutt T J Clin Med. 2024; 13(17).

PMID: 39274365 PMC: 11396319. DOI: 10.3390/jcm13175152.


Clinical Utility of Recently Food and Drug Administration-Approved IntelliSep Test (Sepsis Biomarker) for Early Diagnosis of Sepsis: Comparison with Other Biomarkers.

Sarani N, Dasgupta A, Enders M, Rowan L, Elsarraj H, Gralnek S J Clin Med. 2024; 13(16).

PMID: 39200994 PMC: 11355800. DOI: 10.3390/jcm13164852.


Determination of vWF, ADAMTS-13 and Thrombospondin-1 in Venous Thromboembolism and Relating Them to the Presence of Factor V Leiden Mutation.

Al-Awadhi A, Marouf R, Jadaon M, Al-Awadhy M Clin Appl Thromb Hemost. 2024; 30:10760296231223195.

PMID: 38225166 PMC: 10793187. DOI: 10.1177/10760296231223195.


Organotypic heterogeneity in microvascular endothelial cell responses in sepsis-a molecular treasure trove and pharmacological Gordian knot.

Cleuren A, Molema G Front Med (Lausanne). 2023; 10:1252021.

PMID: 38020105 PMC: 10665520. DOI: 10.3389/fmed.2023.1252021.